Chimeric anti-CD20 monoclonal antibody that depletes B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes CD20-positive cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and induces complement-dependent cytotoxicity and Fc-mediated ADCC by NK cells/macrophages; CD20 crosslinking can also trigger apoptosis.
Autologous tumor-infiltrating lymphocyte (TIL) adoptive cell therapy; ex vivo–expanded patient T cells (primarily CD8+/CD4+) recognize melanoma neoantigens via TCRs and mediate direct tumor cytotoxicity.
Autologous, ex vivo–expanded tumor-infiltrating T cells with native TCRs recognize patient-specific melanoma neoantigens/tumor antigens and mediate direct tumor killing via perforin/granzyme cytotoxicity and cytokine release.
YES
DIRECT
Infused TILs recognize the patient-specific peptide–HLA complex via native TCRs and kill the presenting cell through perforin/granzyme-mediated cytotoxicity (and Fas/FasL apoptosis).
Autologous tumor-infiltrating lymphocyte (TIL) adoptive cell therapy; ex vivo–expanded patient T cells (primarily CD8+/CD4+) recognize melanoma neoantigens via TCRs and mediate direct tumor cytotoxicity.
Autologous, ex vivo–expanded tumor-infiltrating T cells with native TCRs recognize patient-specific melanoma neoantigens/tumor antigens and mediate direct tumor killing via perforin/granzyme cytotoxicity and cytokine release.
YES
DIRECT
Infused autologous TILs recognize tumor peptide–HLA via native TCRs and directly kill target cells by immunologic synapse formation with perforin/granzyme release (and Fas–FasL–mediated apoptosis), aided by cytotoxic cytokines.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and induces complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes CD20-positive cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and kills via complement-dependent cytotoxicity and Fc-mediated ADCC (engaging NK cells/macrophages), with additional direct apoptosis upon CD20 crosslinking.
Polyclonal antibody preparation that depletes T lymphocytes for induction immunosuppression.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity and Fc-mediated ADCC, with additional T-cell apoptosis and functional inhibition, producing potent immunosuppression.
YES
DIRECT
ATG antibodies bind CD11a on T cells and induce complement-dependent lysis and Fc-mediated ADCC, with additional apoptosis, directly depleting CD11a+ cells.